Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
HGH is actually closely related to IGF-1, in a lot of ways. HGH, or GH in short, is certainly an effective fat burner and anabolic agent, and is a protein secreted by the pituitary. Once secreted, it has the ability to influence various cells in the body to increase in number and size, as well as having the ability to enhance the movement of amino acids through cell membranes- thereby increasing the rate at which the cells can convert those molecules to usable proteins. It also causes cells to preferentially burn fat in lieu of carbohydrates. The important thing to realize is that there is a mounting body of evidence that strongly suggests that these effects occur as a result of the IGF-1 released as a result of the pituitaries GH secretion. Scientists have discovered that many of HGHs anabolic and regenerative effects are actually mediated by IGF-1. HGH indirectly causes muscle growth by stimulating the release of IGF-1 when it (the HGH) is destroyed in the human body. So one way you could look at it as HGH being a precursor to IGF-1. The later is more effective at directly causing muscle growth and density increases than HGH. Over the past few decades, HGH has developed quite a reputation for taking awhile (often several weeks) for the user to start seeing results. In contrast, IGF-1 often begins to product noticeable results within the first couple of weeks. With growth hormone you need to use high amounts of anabolics and often insulin to see any gains at all, this is not the case with IGF-1. IGF-1s superiority to HGH is not only intuitive at some level, but has also been clearly elucidated clinically as well. In the following graphs taken from a rodent study comparing IGF-1 and HGH, a low dose as well as a high dose of IGF-1 was shown to be more anabolic than HGH. In comparison to HGH, IGF-1 produced an overall greater total protein content within the injected muscle as well as a greater final weight of the that muscle (called the Tibialis Anterior or TA)
Hopefully, were going to see some movement in the payor coverage of these drugs in the future
It is expected to be packaged in a dual-chamber device for once-weekly SC injection
Patients who switch between brand-name and compounded versions should monitor for any changes in their response or side effects and report these to their healthcare provider
Research studies and clinical trials have shown that GHK-Cu has a favorable safety profile and does not cause adverse events in test subjects
Our goal is to enhance, not alter, your natural beauty
